In vivo mallard experiments indicate that zanamivir has less potential for environmental influenza A virus resistance development than oseltamivir
- 1 December 2017
- journal article
- research article
- Published by Microbiology Society in Journal of General Virology
- Vol. 98 (12) , 2937-2949
Abstract
Neuraminidase inhibitors are a cornerstone of influenza pandemic preparedness before vaccines can be mass-produced and thus a neuraminidase inhibitor-resistant pandemic is a serious threat to public health. Earlier work has demonstrated the potential for development and persistence of oseltamivir resistance in influenza A viruses exposed to environmentally relevant water concentrations of the drug when infecting mallards, the natural influenza reservoir that serves as the genetic base for human pandemics. As zanamivir is the major second-line neuraminidase inhibitor treatment, this study aimed to assess the potential for development and persistence of zanamivir resistance in an in vivo mallard model; especially important as zanamivir will probably be increasingly used. Our results indicate less potential for development and persistence of resistance due to zanamivir than oseltamivir in an environmental setting. This conclusion is based on: (1) the lower increase in zanamivir IC50 conferred by the mutations caused by zanamivir exposure (2–17-fold); (2) the higher zanamivir water concentration needed to induce resistance (at least 10 µg l−1); (3) the lack of zanamivir resistance persistence without drug pressure; and (4) the multiple resistance-related substitutions seen during zanamivir exposure (V116A, A138V, R152K, T157I and D199G) suggesting lack of one straight-forward evolutionary path to resistance. Our study also adds further evidence regarding the stability of the oseltamivir-induced substitution H275Y without drug pressure, and demonstrates the ability of a H275Y-carrying virus to acquire secondary mutations, further boosting oseltamivir resistance when exposed to zanamivir. Similar studies using influenza A viruses of the N2-phylogenetic group of neuraminidases are recommended.Keywords
This publication has 56 references indexed in Scilit:
- Is low pathogenic avian influenza virus virulent for wild waterbirds?Proceedings Of The Royal Society B-Biological Sciences, 2013
- Effect of Oseltamivir Carboxylate Consumption on Emergence of Drug-Resistant H5N2 Avian Influenza Virus in Mallard DucksAntimicrobial Agents and Chemotherapy, 2013
- Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling studyThe Lancet Infectious Diseases, 2012
- Deep Sequencing Reveals Mixed Infection with 2009 Pandemic Influenza A (H1N1) Virus Strains and the Emergence of Oseltamivir ResistanceThe Journal of Infectious Diseases, 2011
- Emergence of H5N1 avian influenza viruses with reduced sensitivity to neuraminidase inhibitors and novel reassortants in Lao People's Democratic RepublicJournal of General Virology, 2010
- The emergence of pandemic influenza virusesProtein & Cell, 2010
- Zanamivir-Resistant Influenza Viruses with a Novel Neuraminidase MutationJournal of Virology, 2009
- In Vitro Generation of Neuraminidase Inhibitor Resistance in A(H5N1) Influenza VirusesAntimicrobial Agents and Chemotherapy, 2009
- Importance of Neuraminidase Active-Site Residues to the Neuraminidase Inhibitor Resistance of Influenza VirusesJournal of Virology, 2006
- Neuraminidase Inhibitor-Resistant and -Sensitive Influenza B Viruses Isolated from an Untreated Human PatientAntimicrobial Agents and Chemotherapy, 2006